Complement Receptors CD21/35 Link Innate and Protective Immunity during Streptococcus pneumoniae Infection by Regulating IgG3 Antibody Responses  by Haas, Karen M. et al.
Immunity, Vol. 17, 713–723, December, 2002, Copyright 2002 by Cell Press
Complement Receptors CD21/35 Link Innate and
Protective Immunity during Streptococcus pneumoniae
Infection by Regulating IgG3 Antibody Responses
opsonization and clearance of S. pneumoniae by anti-
capsular antibody (Brown et al., 1981). Furthermore, C3-
deficient (C3/) mice have impaired clearance of S.
pneumoniae (Circolo et al., 1999). The decoration of
pathogen-derived antigens with C3 breakdown frag-
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responses (Fischer et al., 1996; Wessels et al., 1995),Birmingham, Alabama 35294
and C3/ mice have reduced TI antibody responses
(Guinamard et al., 2000; Ochsenbein et al., 1999). C3
cleavage products such as C3d form covalent bondsSummary
with foreign antigens or pathogens and thereby provide
ligands for leukocyte complement receptors 1 (CR1,The CD21/35 receptor provides an important link be-
CD35) and 2 (CR2, CD21). Human CD21 and CD35 aretween innate and adaptive immunity. Its importance
encoded by distinct genes, while mouse CD21 and CD35during protective immune responses to encapsulated
are alternatively spliced products of the same Cr2 geneextracellular bacteria was assessed using a new line
(Fearon and Carroll, 2000). In mice, CD35 is generatedof mice completely deficient in CD21/35 expression
by the addition of six short consensus repeat units(CD21/35/). CD21/35 expression was essential for
(SCRs) to the amino terminal end of the CD21 proteinthe rapid trapping of C3dg-antigen complexes by B
composed of 15–16 SCRs. Thus, in mice, CD35 servescells in vivo, especially in splenic marginal zones. De-
as a receptor for C4b and C3b as well as the CD21spite normal B cell development in CD21/35/ mice,
ligands, C3d and iC3b (Fearon and Carroll, 2000). CD21/T cell-independent and -dependent antibody re-
35 is expressed primarily by mature B cells and follicularsponses to low-dose antigens were significantly de-
dendritic cells where it associates with CD19, a membercreased, with a striking impairment in IgG3 responses.
of the immunoglobulin (Ig) superfamily that functions asAccordingly, CD21/35/ mice were more susceptible
a response regulator of transmembrane signals duringto acute lethal Streptococcus pneumoniae infection.
B cell activation (Poe et al., 2001). CD21/35 plays anThus, CD21/35 expression is critical for early protec-
important role in enhancing TD antibody responses astive antibody responses to lethal pathogens that rap-
treatment with either anti-CD21 mAb (Heyman et al.,idly multiply and quickly overwhelm the immune
1990; Thyphronitis et al., 1991) or soluble receptor (Heb-system.
ell et al., 1991) impairs humoral immune responses.
Mice with a genetically disrupted Cr2 locus generate
Introduction
modest TD antibody responses to challenge with low-
dose antigens (Ahearn et al., 1996; Molina et al., 1996)
Protection against extracellular bacterial infections re- but generate near normal primary responses to high-
lies on complex and overlapping interactions between dose TD antigens, antigen/adjuvant challenge, or during
innate and adaptive immune responses. Innate protec- secondary responses (Chen et al., 2000; Hasegawa et
tion includes complement activation since comple- al., 2001; Molina et al., 1996; Wu et al., 2000). By contrast,
ment-deficient patients are susceptible to infections the role of CD21/CD35 in TI antibody responses is un-
with encapsulated bacteria such as Streptococcus known except that protective TI antiviral antibody re-
pneumoniae, the predominant cause of community- sponses depend on C3 but not CD21/CD35 expression
acquired pneumonias, septicemia, otitis media, and (Ochsenbein et al., 1999). However, this discrepancy
meningitis (Burman et al., 1985; Figueroa and Densen, may be explained by the finding that the CD21/35-defi-
1991). The C3 complement component is particularly cient mouse line used for those experiments (Ahearn et
important for the efficient opsonization, lysis, and clear- al., 1996) expresses a hypomorphic cell surface CD21/
ance of bacteria (Botto and Walport, 1993; Winkelstein, 35 protein (Hasegawa et al., 2001). In these mice, splic-
1981). Administration of cobra venom factor (CVF), a ing-out of the gene-targeted exon in the Cr2 locus re-
convertase analog that depletes C3, leads to impaired sults in a smaller cell surface CD21/35 protein (CD21/
35hypo) expressed at 40% of wild-type levels that may
retain ligand binding activity. Therefore, a mouse line5 Correspondence: thomas.tedder@duke.edu
6 These authors contributed equally to this work. completely deficient in CD21/35 expression was gener-
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Figure 1. CD21/35/ Mouse Generation by Targeted Disruption of the Cr2 Gene
(A) Restriction map of the region of the Cr2 gene targeted. Signal sequence (SS) and SCR domains are indicated.
(B) The Cr2 targeting vector showing the location of the thymidine kinase (tk) and neomycin-resistance (neor) genes. Genomic DNA between
BstEII and HpaI restriction sites including the signal sequence was replaced with the neor gene in the 5 to 3 orientation. Blunt end ligations
resulted in loss of a BstEII, HpaI, and XbaI site in the targeting construct.
(C) Predicted restriction map of the targeted allele. Homologous recombination increases the BstEII cleavage product from 5.7 to 14 kb.
(D) PCR and Southern blot analysis of genomic DNA from wild-type, CD21/35/, and CD21/35/ littermates. PCR amplification used a 3
primer outside of the targeted region in combination with either a neo-specific primer or control primer specific for the 3 flanking sequence
(as indicated in [C]) to yield PCR products that were 1.8 and 1 kb size, respectively. Southern blot analysis was conducted using BstEII
digestion and a probe specific for the 5 flanking sequence as diagrammed in (C).
(E) Spleen Cr2 mRNA transcripts in wild-type (WT), CD21/35hypo, and CD21/35/ mice. PCR products were amplified using the primer sets
indicated. -actin primers and a water blank were included as controls.
(F) Western blot analysis of CD21/35 protein expression in purified spleen B cell lysate from CD21/35/, CD21/35hypo, and wild-type mice
using CD21/35-specific polyclonal antisera (D-19).
ated in the current study to assess the importance of exon encoding the transcription initiation and signal se-
quence of the CD21/35 protein product with a NeomycinCD21/35 function during responses to TI antigens and
foreign pathogens that rapidly multiply and may quickly resistance (neor) cassette that terminated translation
(Figures 1A–1C). Chimeric mice resulting from two tar-overwhelm the immune system. The complete genetic
disruption of CD21/35 expression had only modest ef- geted ES clones were used to generate two independent
CD21/35/ mouse lines with transmission of the muta-fects on B cell development but revealed a pivotal role
for CD21/35 in establishing protective immunity against tion verified by Southern blot and PCR analysis (Figure
1D). Mice heterozygous for the targeted allele werelethal S. pneumoniae infection.
mated to generate wild-type, CD21/35/, and CD21/
35/ littermates at the expected Mendelian frequency.Results
No phenotypic or functional differences were observed
between individual CD21/35/ mouse lines, so the re-Generation of CD21/35/ Mice
CD21/35/ mice were generated using a targeting con- sults from only one CD21/35/ mouse line are de-
scribed.struct with the 5 promoter region of the Cr2 gene de-
leted (Figure 1). Homologous recombination in embry- Disrupted Cr2 gene transcription was confirmed by
PCR analysis of transcripts produced in spleens of wild-onic stem cells replaced the Cr2 promoter region and
T Cell-Independent Ab Responses Require CD21/35
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type and CD21/35/ littermates in comparison with re- of B cells, independent of their antigen-receptor speci-
ficity.sults from CD21/35hypo splenocytes (Ahearn et al., 1996).
Signal sequence encoding transcripts were found in
wild-type and CD21/35hypo mice but not in CD21/35/ B Cell Development in CD21/35/ Mice
mice (Figure 1E, ss-exon 1 and ss-exon 7 PCR products). CD21/35/ mice had normal frequencies of B220loCD43
Transcripts downstream of the targeted signal se- pro-B cells, IgMB220lo pro/pre-B cells, and B220loIgM
quence were detected in CD21/35/ mice (Figure 1E, immature and B220hiIgM mature B cells in the bone
exons 14a-17 PCR product), suggesting alternative tran- marrow (Table 1). Similarly, blood, spleen, Peyer’s patch,
scription start sites in the Cr2 locus or the generation lymph node, and peritoneal B cell numbers and frequen-
of transcripts extending beyond the Neo insertion site. cies were similar between CD21/35/, CD21/35/, and
Nonetheless, purified splenic B cells from CD21/35/ CD21/35/ littermates. Peritoneal B1 (B220CD11b),
mice did not express detectable CD21/35 protein in B1a (B220loCD5; CD11bCD5), and B-2 plus B1b
Western blot assays using antibodies reactive with the (B220CD5) B cell frequencies and numbers were also
amino or carboxyl terminus of CD21/35 (Figure 1F and similar for CD21/35/ and wild-type littermates (Table
data not shown). By contrast, CD21/35hypo mice ex- 1 and Figure 2F). Although no significant differences
pressed a shorter CD21/35 protein (Figure 1F) reflecting were detected in the frequency or absolute numbers of
transcripts lacking exons 15/16 (Figure 1E) that were splenic B220IgM B cells, there were differences in B
produced at 30% of wild-type levels in CD21/35hypo mice cell subsets as determined by IgM and IgD expression
as determined by real-time PCR analysis (data not levels. Specifically, the IgMhiIgDlo B cell population con-
shown). Thus, the CD21/35/ mice described in this stituting marginal zone, B1, and immature transitional 1
study did not express detectable CD21/35 protein. (T1) B cells (Loder et al., 1999) was significantly ex-
panded in CD21/35/ mice, while the IgMloIgDhi popula-
tion constituting follicular and mantle zone B cells (LoderCD21/35 Function in CD21/35/ Mice
et al., 1999) was significantly decreased compared toCell-surface CD21/35 expression was not detected on
wild-type littermates (Table 1 and Figure 2G). Spleencells from CD21/35/ mice using the CD21/35-specific
marginal zones were well developed in CD21/35/ miceantibodies, 7G6 and 7E9 (Figure 2A). Similarly, lympho-
as assessed by IgM/PNA as well as IgM/IgD immuno-cytes from CD21/35/ mice failed to effectively bind
histochemical staining (Figure 3A and data not shown),C3dg-streptavidin-phycoerythrin (C3dg-SA-PE) tetra-
and differences in the frequency of splenic B1amers (Figures 2B and 2C), which are used to visualize
(CD5IgMhiIgDlo) cells were not found in CD21/35/CD21 ligand binding (Henson et al., 2001). By contrast,
mice (data not shown). Therefore, the expanded popula-B cells from CD21/35hypo mice expressed cell surface
tion of IgMhi splenocytes in CD21/35/ mice most likelyCD21/35 at 40% of the density found on B cells from
represents marginal zone B cells.wild-type littermates and bound C3dg-SA-PE com-
plexes (Figures 2A–2C). Blood and spleen B220 lym-
CD19 Expression by CD21/35/ B Cellsphocytes from wild-type mice also bound C3dg-SA-PE
Since CD21/35hypo B cells express CD19 at30% highercomplexes efficiently compared with nonspecific
density (Hasegawa et al., 2001), B cells from CD21/35/chicken- globulin (CGG)-SA-PE control complexes
mice were similarly examined for altered CD19 expres-(Figures 2B and 2C). Thus, CD21/35/ B cells did not
sion. Although immature B220lo bone marrow B cellsexpress functional CD21/35 protein, while B cells from
from CD21/35/ mice expressed CD19 at normal levelsCD21/35hypo mice expressed CD21/35 that specifically
(91  8% of wild-type), CD21/35/ blood (133  3%),bound C3dg complexes.
spleen (148 13%), lymph node (149 9%), and perito-The contribution of CD21/35 function to C3dg-com-
neal CD5 B cells (139 7%), all expressed significantlyplex binding in vivo was assessed by intravenously ad-
higher levels of CD19 compared to wild-type littermatesministering C3dg-SA-PE or CGG-SA-PE control com-
(Figure 2H; n  5–7, p 	 0.05). Peritoneal CD5 B cells,plexes in CD21/35/ or wild-type littermates. Thirty
which express low levels of CD21/35, had negligibleminutes following injection, C3dg-SA-PE complexes
increases in CD19 expression in the absence of CD21/failed to localize in the splenic marginal zones of CD21/
35 expression (109 3%, n 5; Figure 2H). Intermediate35/ mice but efficiently decorated the marginal zones
increases in CD19 expression were observed for CD21/of wild-type mice (Figure 2D). Trapping of CGG-SA-PE
35/ B cells. These findings demonstrate a direct in-complexes in either CD21/35/ or wild-type mice was
verse relationship between CD21/35 expression andmodest compared with C3dg-SA-PE localization in wild-
CD19 density on the cell surface. Although overall IgMtype mice. Furthermore, splenic B220 B cells isolated
expression was increased on splenic CD21/35/ Bfrom CD21/35/ mice injected with complexes did not
cells, this was mainly due to a decrease in the IgMloIgDhibind C3dg- or CGG-tetramers as visualized by flow cy-
population and increase in the IgMhiIgDlo population (Fig-tometry analysis (Figure 2E). By contrast, a significant
ure 2G). Significant alterations in IgM expression werepercentage of B cells from wild-type mice injected with
not found for B cells from blood, Peyer’s patches, orcomplexes demonstrated measurable C3dg-tetramer
lymph nodes of CD21/35/ mice.binding and modest binding of CGG-SA-PE control
complexes (Figure 2E). Thus, CD21/35 expression is crit-
ical for the rapid trapping of C3dg-antigen complexes in Impaired Humoral Immune Responses
in CD21/35/ Micevivo, especially in splenic marginal zones. Furthermore,
CD21/35 expression allows the efficient cell surface lo- Serum IgM, IgG1, IgG2b, and IgG3 levels were signifi-
cantly reduced in 2-month-old CD21/35/ littermates,calization of C3dg-complexes on a substantial fraction
Immunity
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Figure 2. Cell-Surface CD21/35 Expression
and Ligand Binding
(A) Splenocytes isolated from CD21/35/
and wild-type littermates, or CD21/35hypo mice
were stained in parallel using 7G6 or 7E9 anti-
bodies and analyzed by flow cytometry. Re-
sults are shown for CD21/35/ (thick line,
upper panels), CD21/35hypo (thick line, lower
panels), and wild-type (thin line) splenocytes.
Dotted lines indicate isotype control staining.
(B and C) C3dg-tetramer binding by blood (B)
and spleen (C) lymphocytes from wild-type
(thin line), CD21/35/ (thick line, upper pan-
els), and CD21/35hypo mice (thick line, lower
panels) as assessed by flow cytometry. Bio-
tinylated CGG complexed to SA-PE served
as a negative control (dotted line).
(D and E) Binding of C3dg-SA-PE complexes
in vivo by CD21/35/ and wild-type lit-
termates. Mice were injected i.v. with 40 
g
C3dg-SA-PE or CGG-SA-PE complexes and
sacrificed 30 min later. (D) Visualization of
C3dg-SA-PE complex trapping in spleen sec-
tions by fluorescence microscopy (original
magnification, 200). (E) Binding of C3dg-
SA-PE to splenic B cells. Single-cell suspen-
sions of spleens harvested from mice injected
with either C3dg-SA-PE or CGG-SA-PE con-
trol complexes were stained with B220-FITC
and analyzed by flow cytometry. The percent-
age of cells binding complexes in vivo is indi-
cated.
(F–H) Phenotypic characteristics of CD21/35/
mice. (F) Normal peritoneal B1a (B220loCD5)
B cell frequencies in CD21/35/ mice as de-
termined by B220 and CD5 staining of lym-
phocyte-gated populations. (G) IgMhiIgDlo B
cell subsets are increased, and IgMloIgDhi B
cell subsets are decreased in spleens of
CD21/35/ mice as assessed by flow cytom-
etry. The percentages of B220-gated cells
falling within the IgMloIgDhi, IgMhiIgDhi, and Ig-
MhiIgDlo gated areas are shown. (H) Increased
CD19 density on the surface of CD21/35/
B cells. Spleen, lymph node, or peritoneal
cells of wild-type (/) and CD21/35/ (/)
mice were stained using an anti-CD19 mAb
with flow cytometry analysis. Peritoneal cells
were also stained for CD5, with CD19 expres-
sion shown for the CD5/CD19 and CD5/
CD19 lymphocyte-gated subpopulations.
while IgG2a and IgA levels were normal (Figure 3D). to TNP-LPS, near-normal IgM responses to TNP-Ficoll,
and normal IgM responses to high-dose SRBC and DNP-Heterozygous CD21/35/ mice had intermediate serum
Ig levels. In agreement with these findings, the frequency KLH challenge (Figure 4). By contrast, IgM antibody re-
sponses of CD21/35/ mice were significantly lowerof spleen germinal centers (GCs) in naive CD21/35/
mice was significantly lower than in wild-type littermates during primary responses to low-dose (5  105) SRBC
challenge, although normal IgM responses were in-(10  3% versus 33  3%; p 	 0.01). However, estab-
lished GCs in naive CD21/35/ mice were similar in size duced with secondary challenge (Figure 4C). Early hap-
ten-specific IgG antibody responses in CD21/35/miceto wild-type GCs (Figure 3A). Thus, CD21/35 is important
for initiating GC development and promoting normal were significantly decreased following TNP-LPS and
DNP-Ficoll immunizations (Figures 4A and 4B). Signifi-serum antibody production.
Consistent with reduced serum Ig levels, CD21/35/ cantly reduced primary and secondary IgG antibody re-
sponses were also observed in CD21/35/ mice follow-mice had defective antibody responses to TI-1 (TNP-
LPS), TI-2 (DNP-Ficoll), and TD antigens (sheep red ing low-dose SRBC challenge (Figure 4C). However,
normal IgG responses were observed with high-doseblood cells [SRBC] and DNP-KLH precipitated in alum)
that varied depending on the amount of antigen chal- SRBC challenge and with DNP-KLH immunization, es-
pecially during secondary responses. Nonetheless, IgG3lenge and antibody isotype being assessed. CD21/35/
mice generated normal hapten-specific IgM responses antibody responses to both TI and TD antigens were
T Cell-Independent Ab Responses Require CD21/35
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Table 1. Frequency and Numbers of B Lymphocytes in CD21/35/ Mice
Percentage of Lymphocytesa Number of Cells ( 105)b
Tissue Phenotype Wild-Type CD21/35/ CD21/35/ Wild-Type CD21/35/ CD21/35/
Bone Marrow B220loCD43 12  2 12  1 13  2
B220loIgM 38  5 37  3 35  2
B220loIgM 19  1 22  2 20  2
B220hiIgM 14  2 16  1 15  1
Blood B220 44  3 44  3 43  3 18  3 22  5 17  4
Peyer’s patches B220 71  4 76  3 72  4 24  6 25  3 17  4
Lymph nodes B220IgM 14  3 12  2 15  3 1.1  0.2 2.4  0.7 1.8  0.6
Spleen B220IgM 54  4 55  5 54  5 280  20 300  50 280  30
IgMloIgDhi 26  2 23  2 18  2* 140  10 120  20 96  10*
IgMhiIgDlo 6.4  0.6 7.0  0.5 8.3  0.4* 31  1 39  7 39  3*
IgMhiIgDhi 18  2 20  3 24  5 88  12 100  20 120  20
Peritoneum IgM 45  4 55  7 51  6 7  2 8  2 9  4
B220loCD5 23  4 25  5 24  4 3  1 3  1 4  2
B220 CD5 29  3 26  4 30  4 4  1 4  1 6  3
B220 CD11b 5.0  1.3 4.3  0.7 5.7  2.3 0.7  0.4 0.4  0.1 0.6  0.4
B220 CD11b 46  5 45  8 47  5 6  2 6  2 8  4
CD11b CD5 23  4 26  5 24  4 3  1 4  1 4  2
a Values represent the mean frequency (SEM) of lymphocytes expressing the indicated surface markers as determined by immunofluorescence
staining with flow cytometry analysis. Results were from five to eight mice of each genotype.
b Mean B cell numbers ( SEM) were calculated based on the total number of cells harvested from each tissue. For blood, values indicate
numbers of cells per ml.
* The percentage or number of cells was significantly different from that of wild-type littermates, p 	 0.05.
severely impaired in CD21/35/ mice. For example, infection in the absence of previous exposure were com-
parable between CD21/35/ and wild-type mice. None-IgG3 titers in pooled sera from CD21/35/ mice were
reduced by 90% in response to haptenated TI-anti- theless, CD21/35 expression contributed to the genera-
tion of protective immunity against S. pneumoniaegens or high- and low-dose DNP-KLH (data not shown).
Heterozygous littermates produced intermediate to nor- infection in littermates surviving challenge with 10–100
cfu of live bacteria. Previous infection with live bacteriamal levels of antigen-specific IgG3.
The frequency of GCs in follicles of CD21/35/ mice at 10–100 cfu provided no protection to CD21/35/
mice rechallenged with a lethal 5000 cfu dose of S.was significantly reduced during responses to low- and
high-dose SRBC challenge (CD21/35/ versus wild- pneumoniae 10 days later, while wild-type littermates
were protected (40%–67% survival; Figure 5B; pooledtype: 44  6% versus 61  4%, low dose, and 46  3%
versus 67  3%, high dose; both p 	 0.05). Low-dose results, p 	 0.05). To test whether immunization with
heat-killed bacteria protected against lethal challenge,DNP-KLH challenge induced 65% fewer GCs in CD21/
35/ mice (21  8% versus 60  5%, p 	 0.01), while mice were immunized with graded doses of heat-killed
bacteria and challenged 10 days later with 5000 cfu ofGC formation was normal in CD21/35/ mice receiving
high-dose DNP-KLH (55 6% versus 48 7%). Despite S. pneumoniae. Immunization with 103 heat-killed WU-2
did not protect against a lethal dose of S. pneumoniaereduced antibody production and lower frequencies of
GCs, immunization-induced increases in GC frequen- in CD21/35/ or wild-type littermates (Figure 5C). How-
ever, immunization with a 100-fold higher dose of heat-cies were proportional between CD21/35/ and wild-
type littermates. In addition, the sizes of GCs in CD21/ killed bacteria (105) provided complete protection in
wild-type littermates, but provided CD21/35/ mice35/mice were not markedly different from those found
in wild-type littermates (Figures 3B and 3C). Therefore, with only partial protection (33% survival) (p 	 0.05,
Figure 5D). Immunization and boosting of mice on day 14CD21/35/ mice had defective antibody responses to
low-dose antigen challenge with a striking failure to gen- with 105 heat-killed bacteria protected all mice against
lethal challenge (Figure 5E), as did a single immunizationerate significant IgG3 antibody responses, even in re-
sponse to high-dose antigens. with 107 heat-killed bacteria (Figure 5F). Thus, CD21/
35 plays a pivotal role in establishing a threshold of
protective immunity against lethal S. pneumoniae in-Impaired Protective Immunity to S. pneumoniae
fection.Infection in CD21/35/ Mice
Reduced protection against infection in CD21/35/Since early antibody responses, especially those of the
mice correlated with low bacteria-specific antibody ti-IgG3 isotype, play a critical role in host defense to extra-
ters. Preimmunization titers of natural antibody reactivecellular encapsulated bacteria, CD21/35/ and wild-
with intact S. pneumoniae were significantly lower intype littermates were challenged with graded doses of
CD21/35/ mice than in wild-type littermates (100 20virulent S. pneumoniae, strain WU-2. The rate of mortal-
versus 210  20, respectively, p 	 0.01; Figure 6A).ity was similar between CD21/35/ mice and their wild-
Ten days following immunization with 105 heat-killedtype littermates with an LD50 between 100–1000 colony
bacteria, WU-2-specific antibody titers were nearlyforming units (cfu) of bacteria (Figure 5A). Thus, early
innate responses required to survive S. pneumoniae 5-fold less in CD21/35/ mice than in wild-type lit-
Immunity
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Figure 4. Antibody Responses of Wild-Type, CD21/35/, and
CD21/35/ Littermates
Figure 3. GC Formation and Serum Ig Levels in CD21/35/ Mice
Antibody responses following TNP-LPS (A) and DNP-Ficoll (B) im-
(A–C) Detection of PNA-GCs (brown) and IgM cells (blue) in munization. Antibody responses following SRBC (C) and DNP-KLH
spleens of naive CD21/35/ and wild-type littermates (A) and during in alum (D) immunization with rechallenge on day 21. Values repre-
secondary responses (day 28) in mice immunized with 5 105 SRBC sent mean OD405 results ( SEM) from individual mice as measured
(B) or mice immunized with 10 
g DNP-KLH in alum (C). by antigen-specific ELISAs for groups of four to five mice of each
(D) Serum Ig levels from 10 naive mice of each genotype at 2 genotype. Significant differences in means between CD21/35/ and
months of age were determined by ELISA. Significant differences wild-type littermates are indicated by asterisks. *, p 	 0.05; **, p 	
between means are indicated by asterisks. *, p 	 0.05; **, p 	 0.01. 0.01.
of 5000 cfu (Figure 5F). Seven days following a boost
termates (438  74 versus 2000  495, respectively, of 107 heat-killed bacteria on day 14, IgM, IgG1, IgG2a,
p	 0.05; Figure 6A). Boosting with 105 heat-killed bacte- and IgG2b titers were similar between CD21/35/ and
ria 14 days following primary immunization raised the wild-type littermates. However, WU-2-specific IgG3 ti-
antibody titers to equivalent levels on day 21 (Figure ters remained 12-fold lower in CD21/35/ mice com-
6A), which correlated with protection from infection (Fig- pared to wild-type littermates. Thus, although CD21/
ure 5E). At this immunizing dose and these time points, 35/ mice initially produced less antibody to S. pneu-
the vast majority of WU-2-specific antibody detected moniae than wild-type mice, increasing the antigen dose
was of the IgM isotype. However, immunizing and boost- and/or the number of immunizations overcame the defi-
ing mice with 107 heat-killed bacteria induced measur- cient antibody response and afforded protection against
able IgG responses (Figure 6B). IgM and IgG2a antibody lethal challenge.
titers in CD21/35/ mice were half those of wild-type
littermates during the primary response, while all other Discussion
IgG isotypes were undetectable in CD21/35/ mice.
Nonetheless, this response provided CD21/35/ mice An important role for CD21/35 during innate and adap-
tive immune responses was reflected in the dramaticwith adequate protection against a lethal dose challenge
T Cell-Independent Ab Responses Require CD21/35
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Figure 6. S. pneumoniae-Specific Serum Antibody Titers for Wild-
Type and CD21/35/ Littermates Immunized with Heat-Killed Bac-
teria
Mice were immunized with 105 (A) or 107 (B) heat-killed cfu WU-2
with a boost on day 14. Bacteria-specific antibody titers were deter-
mined by ELISA using 3-fold serial dilutions beginning at 1:100.Figure 5. Survival of Wild-Type and CD21/35/ Littermates follow-
Whole Ig titers were determined for serum samples from individualing S. pneumoniae Challenge
mice (A and B) while isotype-specific titers (B) were determined for(A) Survival of naive mice following infection with S. pneumoniae.
pooled sera. Titers represent results from five to six mice/group(B) Sublethal primary infection provides partial protection against a
with reciprocal titers 200 indicated (	). For whole Ig titers, valueshigh-dose challenge in wild-type but not CD21/35/ littermates.
represent the mean titer ( SEM) with significant differences be-Ten days after the primary infection, mice were rechallenged with
tween means indicated by asterisks. *, p 	 0.05; **, p 	 0.01.a lethal dose of bacteria (5000 cfu).
(C–E) Mice were immunized once with 103 (C), 105 (D), twice with
105 cfu at days 0 and 14 (E), or once with 107 (F) heat-killed cfu and expression significantly enhanced protective humoral
challenged with 5000 cfu of live bacteria 10 (C, D, and F) or 7 (E) immune responses to immunization or subsequent bac-
days later. Five to ten mice of each genotype were used for each
terial challenge. Complete protection of CD21/35/challenge dose.
mice during bacterial challenge was achieved when
mice were given either multiple immunizations or 100-
fold higher doses of immunogenic heat-killed bacteria.susceptibility of CD21/35/ mice to acute lethal S.
pneumoniae infection, despite immunization. Although These results indicate an impaired ability of low-concen-
tration antigens to rapidly generate protective re-naive CD21/35/and wild-type littermates were equiva-
lent in their susceptibility to acute challenge, CD21/35 sponses in CD21/35/ mice, despite the intrinsic adju-
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vanticity of intact bacteria. Since CD21/35 selectively al., 1986; McLay et al., 2002). In humans, IgG2 is the
major IgG isotype produced in response to most TI anti-targets antibody-antigen-C3d complexes to B cells and
follicular dendritic cells (FDCs) (Fang et al., 1998; Wu et gens during late ontogeny (Shackelford et al., 1988).
Human IgG2 deficiency is associated with increasedal., 2000), CD21/35 is likely to also selectively focus
bacterial antigens to these cells during acute infections. susceptibility to chronic sinopulmonary infections, high-
lighting its importance in resistance to encapsulatedThereby, CD21/35 expression may facilitate the pro-
cessing and presentation of antigens at low concentra- bacteria (Kuijpers et al., 1992). Mouse IgG3 demon-
strates superior binding to polysaccharide antigenstions, particularly in the absence of preformed or natural
antibodies where Fc receptor interactions may also fa- which results in enhanced activation of effector function,
including complement activation and Fc receptor bind-cilitate immune complex processing (Thornton et al.,
1994). Alternatively, intrinsic defects in B cell function ing (Greenspan and Cooper, 1993). Therefore, deficient
IgG3 production by CD21/35/mice may be the primarymay result from CD21/35 deficiency although B cells
from CD21/35/ mice (data not shown) function nor- explanation for their increased susceptibility to bacterial
infection. Given the essential role of B cells in protectionmally during in vitro assays. The impaired antibody re-
sponses of CD21/35/ mice to TI and TD antigens may from encapsulated bacteria (Wardemann et al., 2002)
and the importance of marginal zone and B1a B cellbe due to the absence of one or more of these multifac-
eted functions, with the requirement for CD21/35 ex- populations in IgG3 responses (Guinamard et al., 2000;
Hardy et al., 1994), localization of C3d complexes topression diminished when antigen or antigen-specific
antibody concentrations exceed threshold levels. these B cell subsets may be central to the generation of
protective antibody responses during acute infections.CD21/35 functions as an important component of the
innate immune system since CD21/35/ mice were un- The production of a third line of CD21/35/ mice
clarifies the functional and phenotypic characteristicsable to focus C3d-bearing complexes to the marginal
zones of splenic follicles or on the surface of B cells in of this genotype since one line was recently found to
express a hypomorphic cell-surface CD21/35 protein atvivo. Many TI and TD antigens activate complement via
the alternative pathway or activate the classical pathway 30%–40% of wild-type levels (Hasegawa et al., 2001).
The CD21/35hypo protein retained its C3d binding region,after binding natural antibodies reactive with pathogenic
microorganisms (Griffioen et al., 1991; Pryjma et al., and CD21/35hypo mice mediated C3dg-tetramer binding
at 30%–40% of wild-type levels. Nonetheless, all three1974). The covalent attachment of C3 cleavage products
thereby provides a mechanism by which antigens can lines of CD21/35/ mice have typical frequencies and
numbers of bone marrow and peripheral B cells. How-be directly targeted to complement receptor-expressing
cells. Indeed, marginal zone B cells express high levels ever, the new line of CD21/35/ mice had a significant
reduction in the size of the IgMloIgDhi population in theof CD21, and pneumococcal polysaccharides (PS) pref-
erentially localize on marginal zone B cells and FDCs spleen, while the IgMhiIgDlo population was expanded.
Increased numbers of IgMhiIgDlo splenocytes in CD21/along with C3 (Peset Llopis et al., 1996). This may explain
why conjugation of C3d to capsular PS augments TI 35/ mice may be explained by an expanded marginal
zone B cell population, as suggested in a previous studyantibody responses (Test et al., 2001). In the absence
of C3 or with decreased levels of CD21/35 expression, using CD21/35hypo mice (Cariappa et al., 2001). The
IgMhiIgDlo B cell expansion is unlikely to representmarginal zone B cells do not bind TNP-Ficoll efficiently
in vivo (Guinamard et al., 2000). In addition, poor respon- expansion of B1a cells, as CD5 splenic B cell frequen-
cies and peritoneal B1a cell numbers were normal insiveness of neonates to TI-2 antigens is attributed to
their insufficient CD21 expression and lack of marginal our CD21/35/ mice, as reported previously for CD21/
35-targeted mice (Molina et al., 1996). Thus, develop-zone B cells (Timens et al., 1989). Thus, CD21/35 may
regulate the production of TI antigen-elicited antibodies ment of the B1a population proceeds normally in the
absence of CD21/35 expression (Hasegawa et al., 2001)by targeting C3d-antigen complexes to marginal zone
B cell populations, which are produced in normal to in contrast to previous reports (Ahearn et al., 1996). This
finding contrasts with the impaired B1a cell develop-augmented numbers even when CD21/35 expression
is reduced. Based on the high level of C3dg-tetramer ment observed in CD19/ mice (Rickert et al., 1995;
Sato et al., 1996). That CD19 deficiency has a morebinding observed for naive B cells in vivo, C3-tagged
complexes may augment CD19 function and thereby significant effect on B cell function than CD21/35 defi-
ciency is explained by CD19 function that is independentenhance B cell transmembrane signaling in a large frac-
tion of B cells. This indicates a critical role for CD21/35 of CD21/35 expression (Hasegawa et al., 2001). Relative
to previously described CD21/35-targeted mouse linesnot only in the rapid trapping of C3d-Ag-complexes in
marginal zones but also in the localization of C3d-decor- (Ahearn et al., 1996; Molina et al., 1996), CD21/35/
mice described herein had reduced numbers of second-ated antigen to B cells in a manner independent of their
antigen receptor specificity. ary follicles before immunization and following second-
ary antigen challenge, lower relative serum Ig levels withA striking characteristic of CD21/35/ mice was their
inability to generate significant IgG3 antibody responses significantly reduced IgM levels, more impaired anti-
body production during primary and secondary re-to TI, TD, and bacterial antigens compared with wild-
type littermates. IgG3 is the major mouse IgG isotype sponses to a low-dose TD antigen (SRBC), and signifi-
cantly reduced IgG3 antibody responses followingproduced in response to TI-2 antigens (Perlmutter et al.,
1978). Mice unable to produce IgG3 in response to TI-2 antigen challenge. Collectively, these results indicate a
dual role for CD21/35 in innate and adaptive humoralantigens, such as xid and 3 gene-disrupted mice, are
more susceptible to pneumococcal infection as IgG3 responses.
In summary, the current studies reveal that CD21/anti-PS antibodies may be the major opsonin (Briles et
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mice between 2–3 months of age housed under specific pathogen-35 is a critical regulator of both TI and TD antibody
free conditions, except during S. pneumoniae challenges in whichresponses, particularly in response to low-level antigen
mice between 2–4 months of age were transferred to a conventionalchallenge. Furthermore, a unique role for CD21/35 in
animal facility prior to infection. All studies and procedures were
promoting IgG3 antibody responses was revealed. Un- approved by the Duke University Animal Care and Use Committee.
doubtedly, the role of CD21/35 in localization of blood-
borne antigens on marginal zone B cells is central to Antibodies and Immunoflourescence Analysis
Biotinylated- or fluorochrome-conjugated antibodies used in thisthese outcomes. Using model antigens, others have pro-
study included: anti-CD21 (7E9, provided by Dr. T. Kinoshita, Osakaposed that marginal zone B cell trapping of antigens
University, Japan; Kinoshita et al., 1988), anti-mouse IgM or IgDhas a critical role in host defense against bacterial
(Southern Biotechnology Associates, Inc., Birmingham, AL), anti-pathogens since the proximity of marginal zone B cells
B220 (RA3-6B2, provided by Dr. R. Coffman, DNAX Research Insti-
to marginal sinuses ensures that they are among the first tute, Palo Alto, CA), goat F(ab)2 anti-rat IgG (HL) (Southern Bio-
population of cells to encounter blood-borne antigens technology), and antibodies reactive with CD21 (7G6), CD19 (ID3),
B220 (RA3-6B2), CD5 (53-7.3), CD11b (M1/70), and CD43 (S7; BD(Martin et al., 2001). Consistent with this, marginal zone
PharMingen, San Diego, CA). Phycoerythrin- and cychrome-conju-B cells generate rapid activation, and proliferative and
gated streptavidin were from PharMingen. Leukocytes (0.5–1 106)Ig secretory responses (Oliver et al., 1999). Thus, TI
were incubated with antibodies at 4C for 25 min, washed, andand TD bacterial antigens that activate complement are
analyzed using a FACScan flow cytometer (Becton Dickinson, San
likely to become focused onto marginal zone B cells by Jose, CA), with positive and negative cell populations determined
virtue of their high-level CD21/35 receptor expression using unreactive isotype-matched antibodies.
and proximal association with the splenic microvascula-
C3dg-Tetramer Stainingture. Thereby, CD21 crosslinking and its activation of
Biotinylated C3dg was produced in AD494(DE3)pLysS bacteria (No-the CD19 regulatory pathway would make B cells more
vagen, Madison, WI) using the pET11d-C3dg-BSP-BirA expressionresponsive to transmembrane signals (Poe et al., 2001).
plasmid and purified as described (Henson et al., 2001). To form
This provides yet another molecular example of how the C3dg tetramers, 0.25 
g streptavidin-phycoerythrin (SA-PE) was
innate and adaptive immune responses cooperatively added to 1 
g of biotinylated C3dg in 100 
l PBS for 45 min at
interact to hasten antigen recognition and enhance the room temperature. Cells were incubated with C3dg-tetramers on
ice, washed, and analyzed by flow cytometry. An equal concentra-generation of nascent humoral immune responses dur-
tion of biotinylated chicken  globulin (CGG) complexed with SA-ing life-threatening encounters with virulent pathogens.
PE was used as a negative control.
To form C3dg-tetramers to be used for injections, 20 
g biotinyl-Experimental Procedures
ated C3dg (or CGG as a control) was incubated with 20 
g SA-PE
in 200 
l PBS at room temperature for 45 min. C3dg was treatedGeneration of CD21/35/ Mice
with polymyxin B-agarose (Sigma, St. Louis, MO) prior to injection.A 12 kb DNA fragment encoding the 5 end of the mouse Cr2 gene
Tetramers (200 
l) were injected into tail veins of mice with spleenswas isolated from a 129/SvJ genomic library, subcloned into pBlues-
harvested 30 min later. Images of spleen sections (5 
M) were cap-cript SK (Stratagene, La Jolla, CA), sequenced, and mapped for
tured at a fixed exposure time using an Optronics MagnaFire digitalrestriction endonuclease sites (Figure 1A). Two DNA fragments
imaging system.flanking the signal sequence were sequentially inserted into a
pBluescript SK-based targeting vector (p594; provided by Dr. D.
Immunizations and S. pneumoniae InfectionsMilstone, Brigham and Women’s Hospital, Boston, MA) containing
Two-month-old mice were immunized intraperitoneally (i.p.) with 10the PGK promoter, neomycin resistance marker, and poly(A) signal
or 100 
g of DNP-KLH (Calbiochem-Novabiochem Corp., La Jolla,sequence from pGK-neo poly(A) (Stratagene; Figure 1B). A 5.7 kb
CA) precipitated in alum and boosted 21 days later. SRBC immuniza-BstEII DNA fragment was blunt-inserted proximal to the HSV-tk
tion was by i.v. tail vein injection of 5  105 or 1  108 SRBCs ingene (Figure 1B). A 1.3 kb HpaI-XbaI DNA fragment upstream of
200 
l of PBS, followed by a boost at day 21. Mice were alsoSCR1 formed the 3 arm of the targeting vector. R1 ES cells were
immunized i.p. with 25 
g of DNP-Ficoll (Solid Phase Sciences, Santransfected with SalI-linearized plasmid DNA and selected for G418
Rafael, CA) or 50 
g of TNP-LPS (Sigma) in PBS.resistance as described (Selfridge et al., 1992). Appropriately tar-
WU-2 strain S. pneumoniae was grown in Todd-Hewitt broth sup-geted ES cell clones were identified by Southern blot analysis of
plemented with 0.5% yeast extract and was frozen as glycerolgenomic DNA digested with BstXI using an 800 bp SpeI-XhoI probe.
stocks at 70C. At the time of infection, bacteria were diluted inTargeted ES clones were then screened using a PCR strategy that
sterile PBS for i.p. injection, and the number of cfus injected wasamplified a region between the signal sequence and SCR1 of the
reconfirmed by enumerating colony growth on blood agar platesCr2 locus external to the targeted vector. The PCR strategy used a
(BAP). Heat-killed WU-2 bacteria were generated by incubating bac-3 primer outside of the targeted vector region in combination with
teria at 60C for 2 hr, with death confirmed by the absence of growtheither a neo-specific primer or an intron-specific primer as indicated
on BAP.in Figure 1C to yield 1.8 and 1 kb PCR products, respectively. Ten
targeted ES clones were microinjected into 3.5-day-old C57BL/6J
Enzyme-Linked Immunosorbent Assays (ELISAs)blastocysts, which were then implanted into pseudopregnant fe-
Hapten-specific and SRBC ELISAs were performed as describedmales. Two of six chimeric offspring from independent ES clones
previously (Hasegawa et al., 2001; Mori et al., 1989). For S. pneumon-were crossed with C57BL/6J mice to generate offspring heterozy-
iae-specific antibody ELISAs, ELISA plates were coated with 100gous for the disrupted Cr2 allele. Offspring were screened by the

l of heat-killed WU-2 diluted to 4  107 cfu/ml in 0.1 M boratePCR strategy described above and by Southern blot analysis of
buffered saline and incubated overnight at 4C. Endpoint titers ofDNA extracted from tail tissue using BstEII digestion and a probe
sera were determined using 3-fold serial dilutions and taken as thespecific for the 5 flanking sequence (BstEII-BamHI; Figure 1A). Mice
reciprocal dilution of serum yielding an OD405 value that was 3-foldheterozygous for the mutated allele were intercrossed to generate
higher than that of the negative control OD with sera omitted.homozygous, heterozygous, and wild-type littermates for use in
experiments.
CD21/35hypo mice (Ahearn et al., 1996) were generously supplied Immunohistochemistry
Serial (5 
m) frozen spleen sections mounted on gelatin-coatedby Dr. Michael Carroll (Center for Blood Research, Harvard Medical
School, Boston, MA). Mice were confirmed homozygous for the neo- slides were fixed in acetone, rehydrated in PBS, blocked in 5%
normal rabbit serum/2% bovine calf serum in PBS, and staineddisrupted Cr2 locus by Southern blot or PCR analysis of genomic
tail DNA (Ahearn et al., 1996). All experiments were carried out using with HRP-conjugated peanut agglutinin (PNA, Sigma) followed by
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detection with 3,3-diaminobenzidine substrate (DAB, Vector Lab- region generates deficient mice with extrahepatic expression of C3
mRNA. Immunopharmacology 42, 135–149.oratories, Burlingame, CA) to visualize GCs. AP-conjugated goat
anti-mouse IgM antibody (Southern Biotechnology) was used in Fang, Y., Xu, C., Fu, Y.-X., Holers, V.M., and Molina, H. (1998). Ex-
conjunction with Vector blue AP substrate kits (Vector Laboratories) pression of complement receptors 1 and 2 on follicular dendritic
to detect follicles. cells is necessary for the generation of a strong antigen-specific
IgG response. J. Immunol. 160, 5273–5279.
Western Blot Analysis Fearon, D.T., and Carroll, M.C. (2000). Regulation of B lymphocyte
Splenic B cells were enriched by removing T cells with anti-Thy1.2 responses to foreign and self-antigens by the CD19/CD21 complex.
antibody-conjugated magnetic beads (Dynal Inc., Lake Success, Annu. Rev. Immunol. 18, 393–422.
NY) and lysed in 1% NP40 lysis buffer. Protein samples were re-
Figueroa, J.E., and Densen, P. (1991). Infectious diseases associ-
solved on a 6% denaturing SDS-PAGE gel and transferred to nitro-
ated with complement deficiencies. Clin. Microbiol. Rev. 4, 359–395.
cellulose. Following blocking, the membranes were incubated with
Fischer, M.B., Ma, M., Goerg, S., Zhou, X., Xia, J., Finco, O., Han,goat anti-mouse CD21/35 polyclonal antisera (D-19 or M-19; Santa
S., Kelsoe, G., Howard, R.G., Rothstein, T.L., et al. (1996). RegulationCruz Biotechnology, Santa Cruz, CA), followed by incubation with
of the B cell response to T-dependent antigens by classical pathwaydonkey anti-goat IgG-HRP (Jackson Immunoresearch Laboratories,
complement. J. Immunol. 157, 549–556.West Grove, PA) and detection by enhanced chemiluminescence
(ECL kit, Pierce, Rockford, IL). Greenspan, N.S., and Cooper, L.J. (1993). Cooperative binding by
mouse IgG3 antibodies: implications for functional affinity, effector
function, and isotype restriction. Springer Semin. Immunopathol.Statistical Analysis
15, 275–291.Data are shown as mean values  SEM. The Student’s t test was
used to determine whether there were significant differences be- Griffioen, A.W., Rijkers, G.T., Janssens-Korpela, P., and Zegers, B.J.
(1991). Pneumococcal polysaccharides complexed with C3d bindtween sample means. Fisher’s exact test was used to analyze differ-
ences in survival between groups following S. pneumoniae infection. to human B lymphocytes via complement receptor type 2. Infect.
Immun. 59, 1839–1845.
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